Ipsen and Probi have agreed to commercialize Probi’s probiotic strain Lactobacillus plantarum 299v (LP299V) in 18 countries, primarily within EU and emerging markets.
This clinically-documented probiotic with patents in the gastro-intestinal field is expected to complement Ipsen’s medical portfolio in gastroenterology.
From Probi’s perspective it could become one of the largest distribution agreements so far and is of high strategic importance for both companies.
Under this new agreement, Probi will supply bulk LP299V capsules and Ipsen will be responsible for packaging, marketing and selling the product.
The product is planned to be marketed primarily through pharmacies.
It is expected to be launched in the first half of 2017 as a food supplement in the European markets, and then, in other key markets such as Russia and China, depending on regulatory approval.
The product will be marketed under Ipsen’s key brand and Probi’s trademark LP299V.
